On 17 January 2017, the application filed by China National Medicines Corporation Ltd. for purchase of assets by issuing shares was unconditionally passed and approved on the 4th meeting of M&A and Reorganization Committee of CSRC.
The project is recognized as an important approach to the overall reform of Sinopharm Group, covering a large amount of information disclosure and external approval by SASAC, Anti-trust Bureau of MOC and CSRC as well as communication with foreign shareholders.
As the special counsel for the company, Grandall Shanghai Office has rendered professional and overall legal services in the whole process, with WU Xiaoliang, Zhou Yijie, LI Qin, SONG Hongchang, PAN Xiaoxiao, WANG Yin, TAO Yanpei, SHENG Yijie and WU Lin servicing the case.